Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 20,163 Shares

Royalty Pharma PLC (NASDAQ:RPRX) CFO Terrance Coyne sold 20,163 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $43.29, for a total transaction of $872,856.27. Following the transaction, the chief financial officer owned 22,885 shares of the company’s stock, valued at approximately $990,691.65. The trade was a 46.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Royalty Pharma Stock Up 1.7%

Shares of NASDAQ RPRX opened at $43.68 on Thursday. Royalty Pharma PLC has a 1 year low of $29.66 and a 1 year high of $43.76. The company has a market capitalization of $25.21 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 1.64 and a beta of 0.42. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The business has a 50-day moving average of $39.74 and a two-hundred day moving average of $37.89.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The firm had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. On average, analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be paid a dividend of $0.235 per share. The ex-dividend date is Friday, February 20th. This represents a $0.94 annualized dividend and a yield of 2.2%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio (DPR) is 66.67%.

Analyst Ratings Changes

RPRX has been the topic of a number of research reports. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday, January 22nd. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. UBS Group upgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target for the company in a research note on Friday, January 30th. Finally, Citigroup lifted their price objective on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $47.50.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors and hedge funds have recently modified their holdings of RPRX. Private Trust Co. NA grew its holdings in Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 790 shares during the last quarter. Financial Consulate Inc. purchased a new position in Royalty Pharma during the third quarter worth $35,000. Larson Financial Group LLC boosted its stake in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Royalty Pharma by 113.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,428 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 760 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Key Royalty Pharma News

Here are the key news stories impacting Royalty Pharma this week:

• Neutral Sentiment: Company scheduled to report quarterly results on Wednesday; calendar reminder that could increase near-term volatility but contains no new operational detail. Royalty Pharma (RPRX) Projected to Post Earnings on Wednesday
• Negative Sentiment: Zacks warns Royalty Pharma likely lacks the setup for an earnings beat in the upcoming report, signaling expectations may be tempered and limiting upside from the print. That kind of guidance can pressure the stock as traders reposition ahead of results. Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
• Negative Sentiment: Terrance P. Coyne, Royalty Pharma’s CFO, executed three large sell transactions Feb 2–4 totaling roughly 243,541 shares for about $10.36M, materially reducing his stake (multiple filings show percentage decreases of 46%–83% in holdings). Large insider selling at the C-suite level often spooks investors and can drive near-term downward pressure. SEC Form 4 — Terrance P. Coyne

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.